Education
About Us
Working with TipRanks
Follow Us
Alpha Cognition Inc (ACOG)
NASDAQ:ACOG
ACOG Stock Chart & Stats
$5.80
<$0.01(0.02%)
At close: 4:00 PM EST
$5.80
<$0.01(0.02%)
Day’s Range― - ―
52-Week Range$3.75 - $11.54
Previous Close$5.43
Volume265.46K
Average Volume (3M)87.53K
Market Cap
$126.10M
Enterprise Value$50.76M
Total Cash (Recent Filing)$35.40M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.42
Next Earnings
Mar 26, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding21,742,104
10 Day Avg. Volume111,240
30 Day Avg. Volume87,535
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.03
Price to Sales (P/S)0.00
P/FCF Ratio-5.49
Enterprise Value/Market Cap0.40
Enterprise Value/Revenue6.83
Enterprise Value/Gross Profit9.35
Enterprise Value/Ebitda-2.73
Forecast
1Y Price Target
$18.00Price Target Upside210.34% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.33
Revenue Forecast (FY)$24.65M
Bulls Say, Bears Say
Bulls Say
Clinical Evidence GenerationPlanned long-term care, real-world effectiveness, and Phase 4 studies aim to generate data on tolerability and dosing that can support regulatory discussions and inform physicians and payers.
Intellectual PropertyPatent issuance for dosing regimens of benzgalantamine expands intellectual property protection and extends exclusivity for ZUNVEYL, strengthening commercial differentiation.
Payer Coverage And AccessNew pharmacy benefit manager contracts and anticipated group purchasing organization agreements are likely to broaden payor coverage and improve patient access to ZUNVEYL.
Bears Say
Commercial Launch ExecutionFailure to execute an optimized or timely launch of ZUNVEYL could delay revenue generation and weaken early market adoption.
Competition And Clinical RiskGreater-than-expected competition or potential clinical setbacks could reduce market share and increase the risk of future dilution.
Reimbursement And Pricing PressurePricing pressure or payer pushback may slow market uptake and limit patient access despite product availability.
Alpha Cognition Inc News
ACOG FAQ
What was Alpha Cognition Inc’s price range in the past 12 months?
Alpha Cognition Inc lowest stock price was $3.75 and its highest was $11.54 in the past 12 months.
What is Alpha Cognition Inc’s market cap?
Alpha Cognition Inc’s market cap is $126.10M.
When is Alpha Cognition Inc’s upcoming earnings report date?
Alpha Cognition Inc’s upcoming earnings report date is Mar 26, 2026 which is in 2 days.
How were Alpha Cognition Inc’s earnings last quarter?
Alpha Cognition Inc released its earnings results on Nov 13, 2025. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.43 by $0.35.
Is Alpha Cognition Inc overvalued?
According to Wall Street analysts Alpha Cognition Inc’s price is currently Undervalued.
Does Alpha Cognition Inc pay dividends?
Alpha Cognition Inc does not currently pay dividends.
What is Alpha Cognition Inc’s EPS estimate?
Alpha Cognition Inc’s EPS estimate is -0.27.
How many shares outstanding does Alpha Cognition Inc have?
Alpha Cognition Inc has 21,742,104 shares outstanding.
What happened to Alpha Cognition Inc’s price movement after its last earnings report?
Alpha Cognition Inc reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.43. Following the earnings report the stock price went down -3.1%.
Which hedge fund is a major shareholder of Alpha Cognition Inc?
Currently, no hedge funds are holding shares in ACOG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alpha Cognition Inc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$18.00 (210.34% Upside)
$18.00 (210.34% Upside)
Blogger Sentiment
Bullish
ACOG Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 16.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $2.0M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
22.51%
12-Months-Change
Fundamentals
Return on Equity
-125.65%
Trailing 12-Months
Asset Growth
820.85%
Trailing 12-Months
Company Description
Alpha Cognition Inc
Alpha Cognition Inc., a clinical stage biopharmaceutical company, engages in the development of treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The company offers ZUNVEYL (benzgalantamine) for the treatment of mild-to-moderate Alzheimer's disease and mild traumatic brain injury. It also develops ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.
ACOG Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a strong positive momentum with significant growth in ZUNVEYL sales and market engagement, supported by a solid financial position. However, challenges such as operating losses and limited payer coverage remain.View all ACOG earnings summariesACOG Stock 12 Month Forecast
Average Price Target
$18.00
▲(210.34% Upside)
Technical Analysis
Sangamo Biosciences
―
Elicio Therapeutics
―
Cognition Therapeutics
―
Lucid Diagnostics
―
Nuvectis Pharma
―
Ownership Overview
16.55% Insiders
0.06% Mutual Funds
42.72% Other Institutional Investors
40.68% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---